A hybrid drug limits resistance by evading the action of the multiple antibiotic resistance pathway

Molecular Biology and Evolution

Volumn 33, Issue 2, 2016, Pages 492-500

  Wang, Kathy K ^a   Stone, Laura K ^a   Lieberman, Tami D ^a   Shavit, Michal ^b   Baasov, Timor ^b   Kishony, Roy ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

antibiotic resistance; experimental evolution; hybrid drug; multidrug resistance

Indexed keywords

CIPROFLOXACIN; FRAMYCETIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENOME; BACTERIAL GROWTH; CONTROLLED STUDY; CROSS RESISTANCE; ESCHERICHIA COLI; EVOLUTION; GENOTYPE; GROWTH INHIBITION; HIGH THROUGHPUT SEQUENCING; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OPERON; PHENOTYPE; CHEMISTRY; DRUG EFFECTS; GENETICS; IC50; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; MUTATION;

ANTI-BACTERIAL AGENTS; BIOLOGICAL EVOLUTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; GENOTYPE; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; MUTATION; PHENOTYPE;

EID: 84964642773     PISSN: 07374038     EISSN: 15371719     Source Type: Journal    
DOI: 10.1093/molbev/msv243     Document Type: Article

References (44)

1. Aires JR, Nikaido H. (2005). Aminoglycosides are captured from both periplasm and cytoplasm by the AcrD multidrug efflux transporter of Escherichia coli. J Bacteriol. 187: 1923-1929
2. Albers CA, Lunter G, MacArthur DG, McVean G, Ouwehand WH, Durbin R. (2011). Dindel: accurate indel calls from short-read data. Genome Res. 21: 961-973
3. Albrecht HA, Beskid G, Chan KK, Christenson JG, Cleeland R, Deitcher KH, Georgopapadakou NH, Keith DD, Pruess DL, Sepinwall J. (1990). Cephalosporin 30-quinolone esters with a dual mode of action. J Med Chem. 33: 77-86
4. Alekshun MN, Levy SB. (1997). Regulation of chromosomally mediated multiple antibiotic resistance: the mar regulon. Antimicrob Agents Chemother. 41: 2067-2075
5. Alekshun MN, Levy SB. (1999). The mar regulon: multiple resistance to antibiotics and other toxic chemicals. Trends Microbiol. 7: 410-413
6. Alovero F, Nieto M, Mazzieri MR, Then R, Manzo RH. (1998). Mode of action of sulfanilyl fluoroquinolones. Antimicrob Agents Chemother. 42: 1495-1498
7. Baba T, Ara T, Hasegawa M, Takai Y, Okumura Y, Baba M, Datsenko KA, Tomita M, Wanner BL, Mori H. (2006). Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol Syst Biol. 2; doi: 10.1038/msb4100050
8. Barbachyn MR. (2008). Recent advances in the discovery of hybrid antibacterial agents. In: Macor JE, Primeau J, editors. Annual reports in medicinal chemistry. Vol. 43. New York: Academic Press. p. 281-290
9. Baym M, Kryazhimskiy S, Lieberman TD, Chung H, Desai MM, Kishony R. (2015). Inexpensive multiplexed library preparation for megabasesized genomes. PLoS One 10: e0128036
10. Blattner FR, Plunkett G, Bloch CA, Perna NT, Burland V. (1997). The complete genome sequence of Escherichia coli K-12. Science 277: 1453-1462
11. Bremner JB. (2007). Some approaches to new antibacterial agents. Pure Appl Chem. 79: 2143-2153
12. Bremner JB, Ambrus JI, Samosorn S. (2007). Dual action-based approaches to antibacterial agents. Curr Med Chem. 14: 1459-1477
13. Cohen SP, McMurry LM, Levy SB. (1988). marA locus causes decreased expression of OmpF porin inmultiple-Antibiotic-resistant (Mar)mutants of Escherichia coli. J Bacteriol. 170: 5416-5422
14. Datsenko KA, Wanner BL. (2000). One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A. 97: 6640-6645
15. Elkins CA, Nikaido H. (2002). Substrate specificity of the RND-Type multidrug efflux pumps AcrB and AcrD of Escherichia coli is determined predominately by two large periplasmic loops. J Bacteriol. 184: 6490-6498
16. Fortin S, Bérubé G. (2013). Advances in the development of hybrid anticancer drugs. Expert Opin Drug Discov. 8: 1029-1047
17. Fourmy D, Recht MI, Puglisi JD. (1998). Binding of neomycin-class aminoglycoside antibiotics to the A-site of 16 S rRNA. J Mol Biol. 277: 347-362
18. Grapsas I, Lerner SA, Mobashery S. (2001). Conjoint molecules of cephalosporins and aminoglycosides. Arch Pharm (Weinheim). 334: 295-301
19. Gu JW, Neu HC. (1990). In vitro activity of Ro 23-9424, a dual-Action cephalosporin, compared with activities of other antibiotics. Antimicrob Agents Chemother. 34: 189-195
20. Hegreness M, Shoresh N, Damian D, Hartl D, Kishony R. (2008). Accelerated evolution of resistance in multidrug environments. Proc Natl Acad Sci U S A. 105: 13977-13981
21. Hubschwerlen C, Specklin J-L, Sigwalt C, Schroeder S, Locher HH. (2003). Design, synthesis and biological evaluation of oxazolidinonequinolone hybrids. Bioorg Med Chem. 11: 2313-2319
22. Imamovic L, Sommer MOA. (2013). Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development. Sci Transl Med. 5: 204ra132
23. Jones RN, Barry AL, Thornsberry C. (1989). Antimicrobial activity of Ro 23-9424, a novel ester-linked codrug of fleroxacin and desacetylcefotaxime. Antimicrob Agents Chemother. 33: 944-950
24. Khodursky AB, Zechiedrich EL, Cozzarelli NR. (1995). Topoisomerase IV is a target of quinolones in Escherichia coli. Proc Natl Acad Sci U S A. 92: 11801-11805
25. Kim S, Lieberman TD, Kishony R. (2014). Alternating antibiotic treatments constrain evolutionary paths tomultidrug resistance. Proc Natl Acad Sci U S A. 111: 14494-14499
26. Kitagawa M, Ara T, Arifuzzaman M, Ioka-Nakamichi T, Inamoto E, Toyonaga H, Mori H. (2006). Complete set of ORF clones of Escherichia coli ASKA library (A Complete Set of E. coli K-12 ORF Archive): unique resources for biological research. DNA Res. 12: 291-299
27. Langmead B, Salzberg SL. (2012). Fast gapped-read alignment with Bowtie 2. Nat Chem Biol. 9: 357-359
28. Lázár V, Pal Singh G, Spohn R, Nagy I, Horváth B, Hrtyan M, Busa-Fekete R, Bogos B, Méhi O, Cseorgo B, et al. (2013). Bacterial evolution of antibiotic hypersensitivity. Mol Syst Biol. 9: 700
29. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, 1000 Genome Project Data Processing Subgroup. (2009). The Sequence Alignment/Map format and SAMtools. Bioinformatics 25: 2078-2079
30. Maneewannakul K, Levy SB. (1996). Identification for marmutants among quinolone-resistant clinical isolates of Escherichia coli. Antimicrob Agents Chemother. 40: 1695-1698
31. Michel J, Yeh P, Chait R, Moellering R, Kishony R. (2008). Drug interactions modulate the potential for evolution of resistance. Proc Natl Acad Sci U S A. 105: 14918
32. Neyfakh AA. (1992). The multidrug efflux transporter of Bacillus subtilis is a structural and functional homolog of the Staphylococcus NorA protein. Antimicrob Agents Chemother. 36: 484-485
33. Okusu H, Ma D, Nikaido H. (1996). AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multipleantibiotic-resistance (Mar) mutants. J Bacteriol. 178: 306-308
34. Pluchino KM, Hall MD, Goldsborough AS, Callaghan R, Gottesman MM. (2012). Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist Updat. 15: 98-105
35. Pokrovskaya V, Baasov T. (2010). Dual-Acting hybrid antibiotics: a promising strategy to combat bacterial resistance. Expert Opin Drug Discov. 5: 883-902
36. Pokrovskaya V, Belakhov V, Hainrichson M, Yaron S, Baasov T. (2009). Design, synthesis, and evaluation of novel fluoroquinolone-Aminoglycoside hybrid antibiotics. J Med Chem. 52: 2243-2254
37. Ramos P, Bentires-Alj M. (2014). Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. Oncogene 34: 3617-3626
38. Robertson GT, Bonventre EJ, Doyle TB, Du Q, Duncan L, Morris TW, Roche ED, Yan D, Lynch AS. (2008). In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with staphylococci and streptococci. Antimicrob Agents Chemother. 52: 2324-2334
39. Robertson GT, Bonventre EJ, Doyle TB, Du Q, Duncan L, Morris TW, Roche ED, Yan D, Lynch AS. (2008). In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus. Antimicrob Agents Chemother. 52: 2313-2323
40. Szybalski W, Bryson V. (1952). Genetic studies on microbial cross resistance to toxic agents. I. Cross resistance of Escherichia coli to fifteen antibiotics. J Bacteriol. 64: 489-499
41. Walsh C. (2003). Antibiotics: actions, origins, resistance. Washington, DC: ASM Press
42. Wolfson JS, Hooper DC. (1985). The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother. 28: 581-586
43. World Health Organization. (2014). Antimicrobial resistance: global report on surveillance. Bull World Health Organ
44. Zhanel GG, Mayer M, Laing N, Adam HJ. (2006). Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-Tazobactam, and tobramycin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 50: 2228-2230